GlobeNewswire
-
Lakefront Creates New Subscription Right Plan
18/11/2026 -
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
18/11/2026 -
PROCEPT BioRobotics® to Participate in the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026
18/11/2026 -
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/11/2026 -
BillionToOne Responds to Inaccurate and Misleading Short Seller Report
18/11/2026 -
InnovAge Holding Corp. Resolves Civil Matter with U.S. Department of Justice & Participating States
18/11/2026 -
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/11/2026 -
ProKidney Names Farah Ali, M.D., M.S., Chief Medical Officer
18/11/2026 -
Commure Ranked No. 1 for Provider Satisfaction in KLAS 2026 Top 20 Report
18/11/2026 -
New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026
18/11/2026 -
SHARP Surgery Center Opens Four-Room Ambulatory Surgery Center in Austin Built Around the SHARP Method
18/11/2026 -
PRF or PRP Hair Treatment: What Actually Separates the Two Platelet Preparations, and Why Patients Are Rarely Told Which One They Receive
18/11/2026 -
Optimi Health Outlines 2027 Plans for OPTI-101 Phase 2b in Major Depressive Disorder and OPTI-201 Phase 3 in PTSD; Announces Shares-for-Debt Settlement
18/11/2026 -
Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid Cancer
18/11/2026 -
Immuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic Cancer
18/11/2026 -
Surgery Partners, Inc. Announces Increased Consent Fee in Consent Solicitation Relating to Surgery Center Holdings, Inc.’s 7.250% Senior Notes due 2032
18/11/2026 -
Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
18/11/2026 -
CMS Finalizes Reassignment of Gastric Alimetry® Test to Higher Payment Level, Increasing Medicare Hospital Outpatient Payment by Approximately 144%
18/11/2026 -
Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045
18/11/2026
Pages